This preprint is under consideration at World Journal of Surgical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases
Yan Li
department of peritoneal cancer surgery, Beijing Shijitan Hospital affiliated to the captial medical university, Beijing, 100038,China
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Breast cancer (BC) has been ranked as the first malignancy most common and the fifth in mortality rate among women in China [1]. Peritoneal metastases from BC is a rare disease and no guideline or international consensus for it.
Objective: To summarize our experiences in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat breast cancer peritoneal carcinomatosis (BC PC).
Methods: This is a retrospective study on the 4 BC PC patients underwent CRS+HIPEC at our center. The clinicopathological features and treatment details on the BC PC patients were analyzed.
Result: The average age at CRS+HIPEC was 59.8 years. The average duration of CRS+HIPEC was 8.8 h. The median number of resected organ areas was 7. Overall survival from CRS+HIPEC were 31, 28, 16 and 52 months. There were no serious adverse events (SAEs) during perioperative period.
Conclusions: The 4 cases provided evidence that integrated therapy with CRS+HIPEC may be a promising strategy to improve outcome for BC PC patients.
Keywords
Breast cancer, Peritoneal carcinomatosis, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy
Figure 1
Figure 2
Figure 3
Figure 4
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 29 May, 2020
No community comments so far
First submitted
On 24 May, 2020
Editor assigned
On 24 May, 2020
Submission checks complete
On 23 May, 2020
Editor invited
On 23 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at World Journal of Surgical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases
Yan Li
department of peritoneal cancer surgery, Beijing Shijitan Hospital affiliated to the captial medical university, Beijing, 100038,China
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 29 May, 2020
No community comments so far
First submitted
On 24 May, 2020
Editor assigned
On 24 May, 2020
Submission checks complete
On 23 May, 2020
Editor invited
On 23 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Breast cancer (BC) has been ranked as the first malignancy most common and the fifth in mortality rate among women in China [1]. Peritoneal metastases from BC is a rare disease and no guideline or international consensus for it.
Objective: To summarize our experiences in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat breast cancer peritoneal carcinomatosis (BC PC).
Methods: This is a retrospective study on the 4 BC PC patients underwent CRS+HIPEC at our center. The clinicopathological features and treatment details on the BC PC patients were analyzed.
Result: The average age at CRS+HIPEC was 59.8 years. The average duration of CRS+HIPEC was 8.8 h. The median number of resected organ areas was 7. Overall survival from CRS+HIPEC were 31, 28, 16 and 52 months. There were no serious adverse events (SAEs) during perioperative period.
Conclusions: The 4 cases provided evidence that integrated therapy with CRS+HIPEC may be a promising strategy to improve outcome for BC PC patients.
Figure 1
Figure 2
Figure 3
Figure 4